Innate Pharma S.A.
IPH.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | €0 | €0 | €0 | €0 |
| - Cash | €0 | €0 | €0 | €0 |
| + Debt | €0 | €0 | €0 | €0 |
| Enterprise Value | €0 | €0 | €0 | €0 |
| Revenue | €0 | €0 | €0 | €0 |
| % Growth | -75.7% | 4.6% | 309.8% | – |
| Gross Profit | -€0 | €0 | €0 | -€0 |
| % Margin | -252.4% | 10.8% | 12.1% | -288.1% |
| EBITDA | -€0 | -€0 | -€0 | -€0 |
| % Margin | -404% | -3.5% | -123.5% | -356.9% |
| Net Income | -€0 | -€0 | -€0 | -€0 |
| % Margin | -391.9% | -14.6% | -117.1% | -436% |
| EPS Diluted | -0.61 | -0.094 | -0.73 | -0.66 |
| % Growth | -548.2% | 87.1% | -10.6% | – |
| Operating Cash Flow | -€0 | -€0 | -€0 | -€0 |
| Capital Expenditures | -€0 | -€0 | -€0 | -€0 |
| Free Cash Flow | -€0 | -€0 | -€0 | -€0 |